# A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

> **NCT02760797** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 38 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Emactuzumab
- **DRUG:** RO7009789

## Key facts

- **NCT ID:** NCT02760797
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-09
- **Primary completion:** 2018-04-06
- **Final completion:** 2018-04-06
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02760797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02760797, "A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02760797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*